HISTO-AI
The HISTO-AI project (2020-2024) is focused on developing innovative AI tools for analyzing tissue images, genetic data, and treatment outcomes to identify better cancer patients who would benefit most from immunotherapy. The project results from a strong public-private partnership between Ellogon.AI, the Netherlands Cancer Institute, and academic hospitals in the Netherlands and Greece.
Cancer remains one of the leading causes of death worldwide, with an estimated 10 million cancer-related deaths in 2024. Despite advancements in treatment, the effectiveness of therapies can vary widely, and personalized approaches are needed to improve outcomes. The HISTO-AI project addresses the growing need for precision in cancer treatment, utilizing AI to analyze medical data and select patients most likely to benefit from immunotherapy, improving survival rates and reducing unnecessary treatments.
The project uses AI algorithms to assess complex medical images and genetic data, identifying key biomarkers such as tumor-infiltrating lymphocytes (TILs) and PD-L1. By automating this process, the AI tools can process large amounts of data and provide accurate results, enabling doctors to make more informed decisions. This solution offers a more efficient and advanced alternative to traditional methods.
The deliverables include a CE-certified AI solution, EIDOS™, which has already been implemented in four Dutch academic hospitals and one Greek hospital. The AI-driven solution has demonstrated high accuracy in predicting treatment responses, and the ongoing OPTIMAL clinical trial will further validate its impact across 30 Dutch hospitals and five other European countries.
More information Hugo Horlings
More information Computational Pathology Lab
